Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
116.98
-2.28 (-1.91%)
Apr 15, 2025, 4:00 PM EDT - Market closed
Biogen Employees
Biogen had 7,605 employees as of December 31, 2024. The number of employees increased by 35 or 0.46% compared to the previous year.
Employees
7,605
Change (1Y)
35
Growth (1Y)
0.46%
Revenue / Employee
n/a
Profits / Employee
n/a
Market Cap
17.12B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7,605 | 35 | 0.46% |
Dec 31, 2023 | 7,570 | -1,155 | -13.24% |
Dec 31, 2022 | 8,725 | -885 | -9.21% |
Dec 31, 2021 | 9,610 | 510 | 5.60% |
Dec 31, 2020 | 9,100 | 1,700 | 22.97% |
Dec 31, 2019 | 7,400 | -400 | -5.13% |
Dec 31, 2018 | 7,800 | 500 | 6.85% |
Dec 31, 2017 | 7,300 | -100 | -1.35% |
Dec 31, 2016 | 7,400 | 50 | 0.68% |
Dec 31, 2015 | 7,350 | -200 | -2.65% |
Dec 31, 2014 | 7,550 | 700 | 10.22% |
Dec 31, 2013 | 6,850 | 900 | 15.13% |
Dec 31, 2012 | 5,950 | 950 | 19.00% |
Dec 31, 2011 | 5,000 | 150 | 3.09% |
Dec 31, 2010 | 4,850 | 100 | 2.11% |
Dec 31, 2009 | 4,750 | 50 | 1.06% |
Dec 31, 2008 | 4,700 | 400 | 9.30% |
Dec 31, 2007 | 4,300 | 550 | 14.67% |
Dec 31, 2006 | 3,750 | 410 | 12.28% |
Dec 31, 2005 | 3,340 | -926 | -21.71% |
Dec 31, 2004 | 4,266 | 539 | 14.46% |
Feb 20, 2004 | 3,727 | 2,732 | 274.57% |
Jan 31, 2003 | 995 | 303 | 43.79% |
Jan 31, 2002 | 692 | 199 | 40.37% |
Jan 31, 2001 | 493 | 86 | 21.13% |
Jan 31, 2000 | 407 | 42 | 11.51% |
Jan 31, 1999 | 365 | 26 | 7.67% |
Dec 31, 1997 | 339 | 71 | 26.49% |
Dec 31, 1996 | 268 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Thermo Fisher Scientific | 125,000 |
AstraZeneca | 92,900 |
Sanofi | 82,878 |
Novartis AG | 75,883 |
Danaher | 63,000 |
Stryker | 53,000 |
BIIB News
- 5 hours ago - Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union - GlobeNewsWire
- 12 hours ago - EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease - Reuters
- 6 days ago - Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag - Seeking Alpha
- 13 days ago - Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease - GlobeNewsWire
- 19 days ago - Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector. - Market Watch
- 22 days ago - Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square - GlobeNewsWire
- 4 weeks ago - Biogen Inc. (BIIB) Stifel 2025 Virtual CNS Forum Conference (Transcript) - Seeking Alpha
- 5 weeks ago - Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients - GlobeNewsWire